Prolonged effect of a new O-glycoPEGylated FVIII (N8-GP) in a murine saphenous vein bleeding model

Manco-Johnson, 2007, Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia, N Engl J Med, 357, 535, 10.1056/NEJMoa067659

Valentino, 2004, Secondary prophylaxis therapy: what are the benefits, limitations and unknowns?, Haemophilia, 10, 147, 10.1111/j.1365-2516.2003.00870.x

Valentino, 2010, Novel drugs to treat hemophilia, Expert Opin Emerg Drugs, 15, 597, 10.1517/14728214.2010.506871

Pipe, 2010, Hemophilia: new protein therapeutics, Hematology Am Soc Hematol Educ Program, 2010, 203, 10.1182/asheducation-2010.1.203

Powell, 2008, Safety and pharmacokinetics of a recombinant factor VIII with PEGylated liposomes in severe hemophilia A, J Thromb Haemost, 6, 277, 10.1111/j.1538-7836.2007.02856.x

Rottensteiner, 2007, PEGylation or polysialylation reduces FVIII binding to LRP resulting in prolonged half-life in murine models, Blood, 110, 10.1182/blood.V110.11.3150.3150

Lillicrap, 2008, Extending half-life in coagulation factors: where do we stand?, Thromb Res, 122, S2, 10.1016/S0049-3848(08)70027-6

Thim, 2010, Purification and characterization of a new recombinant factor VIII (N8), Haemophilia, 16, 349, 10.1111/j.1365-2516.2009.02135.x

Stennicke, 2013, A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models, Blood, 121, 2108, 10.1182/blood-2012-01-407494

Pastoft, 2012, A sensitive venous bleeding model in haemophilia A mice: effects of two recombinant FVIII products (N8 and Advate®), Haemophilia, 18, 782, 10.1111/j.1365-2516.2012.02780.x

Bi, 1995, Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A, Nat Genet, 10, 119, 10.1038/ng0595-119

Lauritzen, 2009, rFVIIa and a new enhanced rFVIIa-analogue, NN1731, reduce bleeding in clopidogrel-treated and in thrombocytopenic rats, J Thromb Haemost, 7, 651, 10.1111/j.1538-7836.2009.03287.x

Manco-Johnson, 2008, Primary prophylaxis prevents the onset of arthropathy: longitudinal results of 603 boys with severe factor VIII deficiency analyzed through the Centers for Disease Control Universal Data Collection (CDC UDC) Study, Blood, 112, 1164, 10.1182/blood.V112.11.3392.3392

Lillicrap, 2010, Improvements in factor concentrates, Curr Opin Hematol, 17, 393, 10.1097/MOH.0b013e32833c06c6

Tarantino, 2003, Surveillance of infectious complications associated with central venous access devices in children with haemophilia, Haemophilia, 9, 588, 10.1046/j.1365-2516.2003.00793.x

Bailon, 2009, PEG-modified biopharmaceuticals, Expert Opin Drug Deliv, 6, 1, 10.1517/17425240802650568

Fishburn, 2008, The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics, J Pharm Sci, 97, 4167, 10.1002/jps.21278

Veronese, 2008, The impact of PEGylation on biological therapies, BioDrugs, 22, 315, 10.2165/00063030-200822050-00004

Yatuv, 2010, Enhancement of the efficacy of therapeutic proteins by formulation with PEGylated liposomes: a case of FVIII, FVIIa and G-CSF, Expert Opin Drug Deliv, 7, 187, 10.1517/17425240903463846

Zeuzem, 2001, Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy, Expert Opin Investig Drugs, 10, 2201, 10.1517/13543784.10.12.2201

Rytting, 2010, PEG-asparaginase for acute lymphoblastic leukemia, Expert Opin Biol Ther, 10, 833, 10.1517/14712591003769808

Mei, 2010, Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment, Blood, 116, 270, 10.1182/blood-2009-11-254755

Østergaard, 2011, Prolonged half-life and preserved enzymatic properties of factor IX selectively PEGylated on native N-glycans in the activation peptide, Blood, 118, 2333, 10.1182/blood-2011-02-336172

Stennicke, 2008, Generation and biochemical characterization of glycoPEGylated factor VIIa derivatives, Thromb Haemost, 100, 920, 10.1160/TH08-04-0268

Röstin, 2000, B-Domain deleted recombinant coagulation factor VIII modified with monomethoxy polyethylene glycol, Bioconjug Chem, 11, 387, 10.1021/bc990137i

Gritsch H Siekmann J Turecek P Varadi K Baxter Int Inc., Baxter Healthcare SA, assignees PEGylated factor VIII (FVIII), useful for treating bleeding disorder associated with functional defects or deficiencies of FVIII

Johansen, 2010, Prolonged effect of GlycoPEGylated rFVIIa (40k-PEG-rFVIIa) in rabbits correlates to activity in plasma, Thromb Haemost, 104, 157, 10.1160/TH09-11-0797

Agersø, 2012, Pharmacokinetics and pharmacodynamics of turoctocog alfa and N8-GP in haemophilia A dogs, Haemophilia, 18, 941, 10.1111/j.1365-2516.2012.02896.x